CPHI [CHINA PHARMAS,] SC 13G/A: cphi_.txt 1 13G/A
[cphi_.txt 1 13G/A]
SVA [SINOVAC BIOTECH] SC 13G/A: (Original Filing)
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) January 31, 2011 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
SVA [SINOVAC BIOTECH] SC 13G/A: (Name of Issuer) Common Stock (Title of Class
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) January 31, 2011 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
SVA [SINOVAC BIOTECH] SC 13G/A: (Original Filing)
[CUSIP No. P8696W104 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands 5 SOLE VOTING POWER NUMBER OF]
SVA [SINOVAC BIOTECH] SC 13G: 1 NAME OF REPORTING PERSON S.S. OR I.R.S.
[1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Royce & Associates, LLC 52-2343049 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York NUMBER OF 5 SOLE VOTING POWER SHARES 3,525,129 BENEFICIALLY 6 SHARED VOTING POWER OWNED BY]
TPI [TIANYIN PHARMACEUTICAL] CORRESP: (Original Filing)
[January 18, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated December 1, 2010, regarding the above-referenced]
TPI [TIANYIN PHARMACEUTICAL] CORRESP: January 18, 2011 Division of Corporate Finance 100
[January 18, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated December 1, 2010, regarding the above-referenced]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[R E C I T A L S NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 1. Amendment Issuance of Additional Shares of Common Stock “ 2. Effective Time 3. Effect on Transaction Documents 4. Governing Law; Jurisdiction 5. Counterparts 6. Severability [REMAINDER OF THIS] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT January 14, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 8 –]
TPI [TIANYIN PHARMACEUTICAL] 8-K: R E C I T A L S
[R E C I T A L S NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 1. Amendment Issuance of Additional Shares of Common Stock “ 2. Effective Time 3. Effect on Transaction Documents 4. Governing Law; Jurisdiction 5. Counterparts 6. Severability [REMAINDER OF THIS] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT January 14, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 Section 8 –]
BSPM [Biostar Pharmaceuticals,] CORRESP: January 13, 2011 Staff Accountant Division of Corporation
[January 13, 2011 Staff Accountant Division of Corporation Finance 100 F Street, N.E. Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the December 29, 2010 comment letter (the “Comment Letter”) to Mr. Ronghua]
